Abstract. As a major in vivo condensation product of indole-3-carbinol, which is mostly present in cruciferous vegetables, 3,3′-diindolylmethane (DIM) has been previously reported with anti-proliferative action in different types of cancer by our group and others. To further elucidate these underlying mechanisms, we examined the effect of DIM on cyclin D1, which was aberrantly overexpressed in various cancer cells and tumors. Herein, we found that DIM downregulated cyclin D1 expression in colorectal cancer cells (CRC), which was independent of PPARγ expression and protease activity. Furthermore, DIM did not affect cyclin D1 mRNA expression, suggesting DIM modulated cyclin D1 expression at the translational level. Subsequently, blocking eIF2α phosphorylation resulted from endoplasmic reticulum (ER) stress restored cyclin D1 in the presence of DIM. Thus, the present study demonstrates that DIM downregulates cyclin D1 through triggering ER stress in human colorectal cancer cells.

Introduction

Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the world. Phytochemicals are promising anticancer agents given their remarkable chemical structure and diverse biological activities (1) and the prevention and treatment of cancer by dietary phytochemicals that inhibit cell growth is an exciting aspect. Subsequently, results from epidemiological studies have shown that the consumption of cruciferous vegetables could contribute to reduce the risk of CRC and other cancers, and the chemoprotective effects of cruciferous vegetables have been reported in carcinogen-induced colon cancer animal models (2).

Indole-3-carbinol (I3C) is a major bioactive component of cruciferous vegetables, such as broccoli, cabbage, Brussels sprouts and cauliflower, which has been paid more attention as a cancer preventive or chemotherapeutic agent (3). As a major acid condensation product of I3C, 3,3′-Diindolylmethane (DIM) is readily detected in the liver and feces of rodents fed I3C, whereas the parent I3C was not detected in these animals, suggesting DIM may contribute to the observed physiological effects of dietary I3C. Indeed, DIM has been documented to inhibit cell proliferation and induce apoptosis in colorectal cancer cells (4), and other types of cancer cells including prostate (5), pancreas (6), breast (7), bladder (8) and hepatoma cancer (9). Mechanistically, DIM suppressed proliferation via activating peroxisome proliferator-activated receptor γ (PPARγ) and Nur77 activity in CRC cells, as well as inducing apoptosis through inactivating AKT and NF-κB activity in breast cancer cells (10). Moreover, DIM and its derivatives induce endoplasmic reticulum (ER) stress-mediated upregulation of death receptor 5 (DR5), causing pancreatic cancer cell apoptosis (6). We have previously reported that DIM stimulates ATF3 expression by ATF4-mediated pathway (4) which mediates apoptosis of colorectal cancer cells (2). Given both ATF3 and ATF4 are closely associated with ER stress response, DIM could trigger ER stress and subsequently induce growth inhibition and apoptosis in CRC.

Cyclin D1, a well-identified oncogenic protein, is often overexpressed in various types of cancer cells and tumors. It plays crucial roles in cell cycle machinery by activating cyclin-dependent kinase (CDK) 4/6, which subsequently phosphorylates and inactivates retinoblastoma protein (pRb), resulting in the progression from GI to S phase of the cell.

Correspondence to: Professor Seung Joon Baek, Laboratory of Signal Transduction, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea E-mail: baeksj@snu.ac.kr

Abbreviations: DIM, 3,3′-diindolylmethane; I3C, indole-3-carbinol; ER, endoplasmic reticulum; CRC, colorectal cancer

Key words: 3,3′-diindolylmethane, cyclin D1, ER stress, eIF2α, PERK
HCT-116 cells were seeded on 6-well plates and RNA interference was performed according to the manufacturer's instruction. PolyJet reagent (SignaGen Laboratories, Rockville, MD, USA) and pcDNA.CD2/S52A-eIF2A plasmid and transient transfection were kind gifts from the mutation of eIF2 alpha construct (pcDNA.CD2/WT-eIF2A). Wild-type and S52A were kept at 37˚C under a humidified atmosphere of 5% CO2, 100 µl/ml penicillin and 100 µg/ml streptomycin. Cells were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). HCT-116 cells were cultured in McCoy's 5A; SW480, HT-29, LoVo and Caco-2 cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). All other reagents were purchased from Thermo Fisher Scientific Inc., (Pittsburgh, PA, USA), unless others specified.

Materials and methods

Reagents. DIM and cycloheximide were purchased from Sigma-Aldrich (St. Louis, MO, USA). MG132 and epoxomicin was obtained from Merck Millipore (Billerica, MA, USA). Antibodies for cyclin D1, cyclin D3, cyclin E, Ubiquitin, Actin, ATF4 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Antibodies against CHOP, PERK and total eIF2α were obtained from Cell Signaling Technology (Danvers, MA, USA). Control siRNA (#6201) and specific siRNA against PERK (#9024) were purchased from Cell Signaling Technology. Cell culture media were purchased from (BioWhittaker, Rockland, ME, USA). All other reagents were purchased from Thermo Fisher Scientific Inc., (Pittsburgh, PA, USA), unless others specified.

Cell culture. Human colorectal adenocarcinoma HCT-116, SW480, HT-29, LoVo and Caco-2 cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). HCT-116 cells were cultured in McCoy's 5A; SW480 and LoVo were cultured in RPMI-1640 and Ham's F-12, respectively; HT-29 and Caco-2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM). All media were supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were kept at 37˚C under a humidified atmosphere of 5% CO2.

Plasmid and transient transfection. Wild-type and S52A mutation of eIF2α alpha construct (pcDNA.CD2/WT-eIF2A and pcDNA.CD2/S52A-eIF2A) were kind gifts from Dr David Ron. Transient transfection was performed using PolyJet reagent (SignaGen Laboratories, Rockville, MD, USA) according to the manufacturer's instruction.

RNA interference. HCT-116 cells were seeded on 6-well plates at a density of 3.0x10⁴ cells/well overnight. Control siRNA and siPERK (Cell Signaling Technology) was transfected at a final concentration of 100 nM using PepMute transfection reagent (SignaGen Laboratories) according to the manufacturer's instruction.

Semi-quantitative reverse transcription PCR. Total RNA of cells was isolated by E.Z.N.A Total RNA kit (Omega Bio-Tek, Inc., Norcross, GA, USA) according to the manufacturer's protocol. Then RNA (1 µg) was reverse transcribed using Verso cDNA synthesis kit (Thermo Fisher Scientific). PCR was performed using GoTaq Green Master Mix PCR Mixture (Promega, Madison, WI, USA) with primers for human cyclin D1, XBP1, ATF3 and GAPDH as follows: cyclin D1, forward, 5'-ATGGAACACCAGCTCCTGTGCTGC-3' and reverse, 5'-TCAGATGTCCACGTCGCACTG-3'; XBP1, forward, 5'-CTTTGTAGTTGAGAACCAGG-3' and reverse, 5'-GGGCTTTGATATATATGGG-3'; ATF3: forward, 5'-GTTGTAGGATTATTGCTAAACAGAC-3' and reverse, 5'-AGCTGCAATTTATTTCTTCTG-3'; GAPDH, forward, 5'-GGGCCTGTTTTAACTCGTG-3' and reverse, 5'-TGGCAGGTATTATTCTAGACGGG-3'. Thermal cycling conditions were as follows: 95˚C for 2 min, followed by 25 cycles of 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 30 sec, and final extension at 72˚C for 5 min. Each PCR product was electrophoresed on agarose gel and viewed using ethidium bromide staining under ultraviolet light. The intensity of bands was analyzed by densitometry using the GAPDH band as a relative control.

Western blot analysis. Cells were washed with phosphate-buffered saline (PBS) and lysed using radio immunoprecipitation assay buffer (50 mmol/l Tris-HCl pH 7.4, 150 mmol/l NaCl, 1 mmol/l EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) supplemented with 1X protease inhibitor cocktail solution (Calbiochem, San Diego, CA, USA) and phosphatase inhibitor (1 mmol/l Na3VO4, 1 mmol/l NaF) and centrifuged at 13,000 x g for 10 min at 4˚C. The supernatants were collected to determine protein concentration by the BCA protein assay (Pierce, Rockford, IL, USA) using bovine serum albumin (BSA) as the standard. Then protein samples (30 µg) were mixed with an equal amount of 2x Laemmli buffer and boiled for 5 min, subsequently subjected to SDS-PAGE. The proteins were transferred to nitrocellulose membranes (Osmonics, Minnetonka, MN, USA), which were blocked with TBS containing 0.1 % Tween-20 (TBST) and 5% non-fat milk for 1 h at room temperature, followed by incubation with a specific primary antibody (1:1,000) in at 4˚C overnight. After three washes with TBST, the blots were incubated with peroxidase-conjugated IgG for 1 h at room temperature, visualized using ECL (Amersham Biosciences, Piscataway, NJ, USA) and quantified by Scion Image Software (Scion Corp., Frederick, MD, USA).

Results

Effect of DIM on cyclin D1 expression in colorectal cancer cells. To investigate the effect of DIM on cyclin expression in colorectal cancer cells, we treated HCT-116 cells with DIM at different dose- and time-dependent manner. As a result, DIM downregulated cyclin D1 and D3 expression in a dose- and time-dependent manner (Fig. 1A and B), but not cyclin E. Since DIM treatment exhibited the strongest decrease in cyclin D1 expression, we further investigated the alteration of cyclin D1 expression in other colorectal cancer cells. Various cancer cells were treated with DIM at different concentration and time. The result indicated that DIM consistently decreased cyclin D1 in SW480, LoVo and CaCo-2 cells (Fig. 1C), suggesting that cyclin D1 downregulation could
be a potential mechanism for the anti-proliferative effect of DIM.

**Effect of DIM on cyclin D1 mRNA expression and protein stability.** To better understand the underlying mechanism by which DIM reduced cyclin D1 expression, we assessed the effect of DIM on cyclin D1 mRNA expression and protein stability. As seen in Fig. 2A, the level of cyclin D1 mRNA was not altered in the presence of DIM. Moreover, we examined cyclin D1 protein stability, showing that DIM did not affect its turnover rate when blocking protein synthesis (Fig. 2B). This result was further examined using proteasomal inhibitor MG-132. As shown in Fig. 2C, a proteasome inhibitor MG-132 marginally restored cyclin D1 expression in the presence of DIM. It is suggested that DIM marginally affects proteasomal pathway for cyclin D1 degradation, although the level of ubiquitinated proteins is increased by blocking ubiquitin-proteasome pathway.

Taking together, DIM deceased cyclin D1 independent of degradation pathway and these data implicated that DIM-induced cyclin D1 downregulation could occur at the translational level.

**Effects of signaling pathways on DIM-mediated cyclin D1 downregulation.** DIM has been reported to inhibit proliferation of colorectal cancer cells through activating PPARγ activity (15). Thus, PPARγ antagonist was treated in HCT-116 cells. As shown in Fig. 3A, cyclin D1 was not affected by a PPARγ antagonist GW9662 in the presence of DIM, indicating that its reduction was not associated with PPARγ activation. To further examine other possible signaling pathways mediated...
by the downregulation of cyclin D1 by DIM, we treated cells with various inhibitors, including proteasome inhibitor epoxomicin, cysteine protease inhibitor leupeptin, serine protease inhibitor PMSF, pan-caspase inhibitor z-VAD-fmk, NF-κB inhibitor Bay 11-7082 (BAY), PKC inhibitor Rottlerin (RO), p38MAPK inhibitor SB203580 (SB), ERK inhibitor PD98059 (PD), and PI3K inhibitor LY294002 (LY). As expected, DIM induced x-box-binding-protein-1 (XBP-1) mRNA splicing and ATF3 expression in a time-dependent manner (Fig. 4A). These are the markers for ER stress. Next, we measured whether PERK, one of the upstream components of eIF2α, contributes to DIM-mediated cyclin D1 downregulation. Blocking PERK did not seem to affect DIM-mediated cyclin D1 downregulation (Fig. 4B), indicating that DIM may affect eIF2α by other kinases. Given the critical role of eIF2α phosphorylation in ER stress-mediated protein translation inhibition, we then asked whether eIF2α protein phosphorylation mediated cyclin D1 downregulation by DIM. As shown in Fig. 4C, transfecting eIF2α construct harboring an S52A mutation attenuated ER stress response as assessed by CHOP and ATF4 upregulation, indeed restoring cyclin D1 expression in the presence of DIM. It suggested that ER stress-mediated protein synthesis inhibition played key roles in cyclin D1 downregulation by DIM in CRC cells.

**Discussion**

There is a large number of evidence showing that the high intake of cruciferous vegetables is inversely associated with the risk of CRC in humans (16). As a major component of cruciferous vegetables, I3C and its condensation product DIM exhibited anti-tumorigenic effect in different types of cancer cells and in animal models (17). Given the important role of I3C/DIM in cancer chemoprevention, the multiple mechanisms responsible for the anti-proliferative effect of DIM have been proposed, including the regulation of cell cycle regulators such as p21, p27, cyclin D1 or E as well as CKDs 2, 4, 6, which in part was attributed to the effect of DIM on Sp1 transcriptional activity (18). Herein, we further identified that cyclin D1 was downregulated by DIM via ER-stress-mediated protein synthesis inhibition, which provided new mechanism for the potential chemopreventive or therapeutic function of DIM in CRC.

It has been documented that I3C induced G1 cell cycle arrest in prostate and breast cancer cells, which is accompanied with cyclin D1 downregulation (19,20). Thus, it is not surprising that we found DIM decreased cyclin D1 in CRC cells. However, cyclin D1 in HT-29 cells was not substantially altered in the presence of DIM (Fig. 1C), which was in agreement with a previous report (15) that DIM analogues like DIM-C-pPhCF3 and DIM-C-pPhBu did not affect the expression of cyclin D1 in HCT-15 or HT-29 cells, suggesting that DIM-induced cyclin D1 downregulation was dependent on cell content.

Several PPARγ agonists have been reported to downregulate cyclin D1 expression at transcriptional or post-transcriptional level as part of the mechanism for causing G1 cell cycle arrest or growth inhibition through receptor-dependent and -independent pathways. We have previously observed that PPARα/γ dual ligand MCC-555 decreased cyclin D1 in pancreatic cancer cells in a PPARγ-dependent manner (21). In contrast, our finding in the present study demonstrated that DIM altered cyclin D1 expression.
independent of PPARγ activity. In addition, a DIM derivate did not affect cyclin D1 expression although it activated PPARγ in CRC cells (15). The evidence suggested that DIM could exhibit multiple growth-inhibitory mechanisms which varies in different types of cancer cells, and is dependent on cell content.

The ubiquitin-proteasome degradation pathway plays a key role in modulating cell cycle regulators, including cyclin D1, since they are short-life proteins. Not surprisingly, the 26s proteasome inhibitors MG-132 and epoximycin both increased basal cyclin D1 expression of HCT-116 cells in the present study (Figs. 2C and 3B). A large number of chemicals or drugs have been documented to trigger cyclin D1 degradation through proteasome pathway (13). DIM and its derivate have also been reported to reduce cyclin D1 in MCF-7 and MDA-MB-231 cells, which was blocked by proteasome inhibitor MG-132 (14). Our finding showed that proteasome inhibitors failed to completely reverse cyclin D1 downregulation in the presence of DIM, indicating DIM did not induce proteasome-dependent cyclin D1 degradation (Fig. 2C). However, we did observe that DIM increased the level of ubiquitinated protein when proteasome activity was blocked, suggesting DIM could target other proteins through activating ubiquitin-proteasome pathway. Indeed, Li et al (22) reported that DIM selectively induced proteasomal degradation of class I histone deacetylases in CRC cells. Moreover, various pathway inhibitors failed to restore cell cyclin D1 expression in the presence of DIM. Although these inhibitors have previously been verified to block specific pathways by our group (23,24), they could harbor other non-identified activities, and induce cell stress by themselves. Therefore, the signaling pathways involved in cyclin D1 downregulation by DIM should be further carefully ruled out.

Accumulating evidence showed that chemicals or drugs harboring anticancer activity were able to trigger ER stress, which contributes to cell cycle arrest and apoptosis. DIM induced apoptosis through ER stress-mediated upregulation of DR5 in pancreatic cancer cells (6). We also reported DIM increased ATF3 and ATF4 expression in CRC cells, both of which can be considered as markers of ER stress. ER stress-mediated eIF2α phosphorylation leads to nearly global protein repression by limiting the delivery of initiator Met-tRNAi to translation machinery, including cyclin D1 (25). In the present study we employed constitutively active eIF2α construct (S52A mutation) which had been documented to attenuate ER stress response in HCT-116 cells (26). As expected, transfection of mutant eIF2α construct weakened DIM-induced ER stress as evaluated by examining CHOP and ATF4 expression, and rescued cyclin D1 expression, suggesting DIM halted cyclin D1 protein translation by triggering ER stress. Moreover, the results were also supported by the observation that neither cyclin D1 mRNA expression nor protein stability was affected by DIM. However, the detailed evidence that DIM inhibited cyclin D1 protein synthesis remains to be further investigated.

Taken together, we presented here that DIM modulated cyclin D1 through activating ER stress response, therefore, providing new insight into its anti-proliferative effect on CRC cells. Given the multiple signaling pathways induced by ER stress, it would be meaningful to clarify DIM-induced ER stress pathways and identify potential anticancer molecules in ongoing investigations.

Acknowledgements

The present study was supported by the Research Resettlement Fund for the new faculty of Seoul National University and partially supported by the Research Institute for Veterinary Science, Seoul National University. The study was also supported in part by the Program in Organizational or Personal Cooperation with Foreign Counterparts (no. 2010630161), the China Scholarship Council, China.

References

7. Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB by DIM involves multiple growth-inhibitory mechanisms which varies in different types of cancer cells, and is dependent on cell content.

Received

7. Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB by DIM involves multiple growth-inhibitory mechanisms which varies in different types of cancer cells, and is dependent on cell content.

Acknowledgements

The present study was supported by the Research Resettlement Fund for the new faculty of Seoul National University and partially supported by the Research Institute for Veterinary Science, Seoul National University. The study was also supported in part by the Program in Organizational or Personal Cooperation with Foreign Counterparts (no. 2010630161), the China Scholarship Council, China.

Received

7. Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB by DIM involves multiple growth-inhibitory mechanisms which varies in different types of cancer cells, and is dependent on cell content.


